{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:52Z","timestamp":1787729632958,"version":"build-2784847793"},"reference-count":21,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"4","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,4]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p>Antimalarial medications are recommended for chemoprevention as part of malaria control programs to decrease the morbidity and mortality related to more than 200 million infections each year. We sought to evaluate patient and provider acceptability of malaria chemoprevention in a long-acting formulation. We administered questionnaires to patients and providers in malaria endemic districts in Kenya and Zambia. Questions explored preferences and concerns around long-acting antimalarial formulations compared with oral formulations. We recruited 202 patient respondents (Kenya, <jats:italic>n =<\/jats:italic> 102; Zambia, <jats:italic>n =<\/jats:italic> 100) and 215 provider respondents (Kenya, <jats:italic>n =<\/jats:italic> 105; Zambia, <jats:italic>n =<\/jats:italic> 110). Long-acting injection was preferred to oral pills, whereas oral pills were preferred to implant or transdermal administration by patient respondents. Of 202 patient respondents, 80% indicated that they \u2018definitely would try\u2019 malaria chemoprevention offered by injection instead of oral pills. Of parents or guardians, 84% of 113 responded that they \u2018definitely would\u2019 have their child age &lt;\u00a012 years and 90% of 88 \u2018definitely would\u2019 have their child \u226512 years receive an injection for malaria prevention. Provider respondents indicated that they would be more likely to prescribe a long-acting injectable product compared with an oral product for malaria chemoprevention in adults (70%), adolescents ages 12 years and older (67%), and children &lt;12 years (81%). Potential for prolonged adverse effects with long-acting products was the highest concern for patient respondents, while higher medication-related cost was cited as the most concerning barrier to implementation by providers. Overall, these findings indicate enthusiasm for the development of long-acting injectable antimalarials to provide individual delivery method options across age groups.<\/jats:p>","DOI":"10.4269\/ajtmh.23-0245","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T14:57:39Z","timestamp":1692629859000},"page":"752-760","source":"Crossref","is-referenced-by-count":2,"title":["Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria Chemoprevention"],"prefix":"10.4269","volume":"109","author":[{"given":"Kimberly K.","family":"Scarsi","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska;"},{"name":"College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan","family":"Sayles","sequence":"additional","affiliation":[{"name":"College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Kapungu","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology, Tropical Diseases Research Centre, Ndola, Zambia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sifuna","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Center, Kenya Medical Research Institute (KEMRI)\/U.S. Army Medical Research Directorate\u2013Africa (USAMRD-A), Kisumu, Kenya;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Ippolito","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland;"},{"name":"The Johns Hopkins Malaria Research Institute, John Hopkins Bloomberg School of Public Health, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renae","family":"Furl","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Anderson","sequence":"additional","affiliation":[{"name":"College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle Dountio","family":"Ofimboudem","sequence":"additional","affiliation":[{"name":"Treatment Action Group, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gershom","family":"Chongwe","sequence":"additional","affiliation":[{"name":"Tropical Diseases Research Centre, Ndola, Zambia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hutter","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Center, Kenya Medical Research Institute (KEMRI)\/U.S. Army Medical Research Directorate\u2013Africa (USAMRD-A), Kisumu, Kenya;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rannard","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Centre of Excellence in Long-Acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"World Malaria Report","year":"2022"},{"key":"b2","series-title":"Global Technical Strategy for Malaria 2016\u20132030, 2021 Update","year":"2021"},{"key":"b3","series-title":"High Burden to High Impact: A Targeted Malaria Response","year":"2019"},{"key":"b4","series-title":"Proc Natl Acad Sci USA","first-page":"24900","article-title":"A new malaria vector in Africa: predicting the expansion range of Anopheles stephensi and identifying the urban populations at risk","volume":"117","author":"Sinka","year":"2020"},{"key":"b5","series-title":"Science","first-page":"1112","article-title":"Toward a chemical vaccine for malaria","volume":"362","author":"Phillips","year":"2018"},{"key":"b6","series-title":"WHO Guidelines for Malaria","year":"2022"},{"key":"b7","series-title":"Lancet","first-page":"1779","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022"},{"key":"b8","series-title":"N Engl J Med","first-page":"595","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021"},{"key":"b9","series-title":"J Int Assoc Provid AIDS Care","first-page":"23259582211009011","article-title":"The promise of improved adherence with long-acting antiretroviral therapy: what are the data?","volume":"20","author":"Scarsi","year":"2021"},{"key":"b10","series-title":"Clin Psychopharmacol Neurosci","first-page":"361","article-title":"Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis","volume":"16","author":"Park","year":"2018"},{"key":"b11","series-title":"N Engl J Med","first-page":"1998","article-title":"Effectiveness of long-acting reversible contraception","volume":"366","author":"Winner","year":"2012"},{"key":"b12","year":"2021"},{"key":"b13","series-title":"Lancet Infect Dis","first-page":"1728","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022"},{"key":"b14","author":"Chounta","year":"2021"},{"key":"b15","series-title":"AIDS Care","first-page":"801","article-title":"Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection","volume":"33","author":"Dandachi","year":"2021"},{"key":"b16","series-title":"Cult Health Sex","first-page":"1066","article-title":"\u201cI feel empowered\u201d: women\u2019s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain","volume":"23","author":"Mantsios","year":"2021"},{"key":"b17","series-title":"J Acquir Immune Defic Syndr","first-page":"190","article-title":"Interest of youth living with HIV in long-acting antiretrovirals","volume":"80","author":"Weld","year":"2019"},{"key":"b18","series-title":"Trop Med Infect Dis","first-page":"58","article-title":"Development of new strategies for malaria chemoprophylaxis: from monoclonal antibodies to long-acting injectable drugs","volume":"7","author":"Moehrle","year":"2022"},{"key":"b19","series-title":"N Engl J Med","first-page":"803","article-title":"A monoclonal antibody for malaria prevention","volume":"385","author":"Gaudinski","year":"2021"},{"key":"b20","series-title":"Parasit Vectors","first-page":"66","article-title":"Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool","volume":"16","author":"Pooda","year":"2023"},{"key":"b21","series-title":"Nat Commun","first-page":"315","article-title":"Long-acting injectable atovaquone nanomedicines for malaria prophylaxis","volume":"9","author":"Bakshi","year":"2018"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/109\/4\/article-p752.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/109\/4\/article-p752.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/109\/4\/article-p752.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T12:47:29Z","timestamp":1696423649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/109\/4\/article-p752.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":21,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.23-0245","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]}}}